Plasmapheresis for Pembrolizumab-Induced Hepatitis in a Patient with Squamous Cell Carcinoma and Prior Orthotopic Liver Transplantation

Checkpoint inhibitor therapy with monoclonal antibodies against programmed cell death protein 1 (PD1) has been implemented in the treatment of numerous malignancies. Pembrolizumab is one such medication. While severe toxicities are very rare, mild immune-mediated reactions with a variety of end orga...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Nattah, Sanaa, Lata Sharma, Kusum, Caldis, Matthew, Spengler, Erin, Rose, William N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799356/
https://www.ncbi.nlm.nih.gov/pubmed/35096431
http://dx.doi.org/10.1155/2022/5908411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799356/
https://www.ncbi.nlm.nih.gov/pubmed/35096431
http://dx.doi.org/10.1155/2022/5908411

Ejemplares similares